BACKGROUND: The long-term effects of combined antiretroviral therapy (cART) on CD4 percentage in HIV-infected children are incompletely understood, with evidence from resource-deprived areas particularly scarce even though most children with HIV live in such settings. We sought to describe this relationship. METHODS: Observational longitudinal data from cART-naive children enrolled between December 2004 and May 2010 into an HIV care and treatment program in Kinshasa, Democratic Republic of Congo were analyzed. To estimate the effect of cART on CD4 percentage while accounting for time-dependent confounders affected by prior exposure to cART, a marginal structural linear mean model was used. RESULTS: Seven hundred ninety children were active for 2090 person-years and a median of 31 months; 619 (78%) initiated cART. At baseline, 405 children (51%) were in HIV clinical stage 3 or 4; 528 (67%) had advanced or severe immunodeficiency. Compared with no cART, the estimated absolute rise in CD4 percentage was 6.8% [95% confidence interval (CI), 4.7% to 8.9%] after 6 months of cART, 8.6% (95% CI, 7.0% to 10.2%) after 12 months, and 20.5% (95% CI, 16.1% to 24.9%) after 60 months. cART-mediated CD4 percentage gains were slowest but greatest among children with baseline CD4 percentage <15. The cumulative incidence of recovery to "not significant" World Health Organization age-specific immunodeficiency was lower if cART was started when immunodeficiency was severe rather than mild or advanced. CONCLUSIONS: cART increased CD4 percentages among HIV-infected children in a resource-deprived setting, as previously noted among children in the United States. More gradual and protracted recovery in children with lower baseline CD4 percentages supports earlier initiation of pediatric cART.
BACKGROUND: The long-term effects of combined antiretroviral therapy (cART) on CD4 percentage in HIV-infectedchildren are incompletely understood, with evidence from resource-deprived areas particularly scarce even though most children with HIV live in such settings. We sought to describe this relationship. METHODS: Observational longitudinal data from cART-naive children enrolled between December 2004 and May 2010 into an HIV care and treatment program in Kinshasa, Democratic Republic of Congo were analyzed. To estimate the effect of cART on CD4 percentage while accounting for time-dependent confounders affected by prior exposure to cART, a marginal structural linear mean model was used. RESULTS: Seven hundred ninety children were active for 2090 person-years and a median of 31 months; 619 (78%) initiated cART. At baseline, 405 children (51%) were in HIV clinical stage 3 or 4; 528 (67%) had advanced or severe immunodeficiency. Compared with no cART, the estimated absolute rise in CD4 percentage was 6.8% [95% confidence interval (CI), 4.7% to 8.9%] after 6 months of cART, 8.6% (95% CI, 7.0% to 10.2%) after 12 months, and 20.5% (95% CI, 16.1% to 24.9%) after 60 months. cART-mediated CD4 percentage gains were slowest but greatest among children with baseline CD4 percentage <15. The cumulative incidence of recovery to "not significant" World Health Organization age-specific immunodeficiency was lower if cART was started when immunodeficiency was severe rather than mild or advanced. CONCLUSIONS: cART increased CD4 percentages among HIV-infectedchildren in a resource-deprived setting, as previously noted among children in the United States. More gradual and protracted recovery in children with lower baseline CD4 percentages supports earlier initiation of pediatric cART.
Authors: W V Raszka; G A Meyer; N J Waecker; D P Ascher; R A Moriarty; G W Fischer; M L Robb Journal: Pediatr Infect Dis J Date: 1994-01 Impact factor: 2.129
Authors: A M van Rossum; H J Scherpbier; E G van Lochem; N G Pakker; W A Slieker; K C Wolthers; M T Roos; J H Kuijpers; H Hooijkaas; N G Hartwig; S P Geelen; T F Wolfs; J M Lange; F Miedema; R de Groot Journal: AIDS Date: 2001-11-23 Impact factor: 4.177
Authors: S E Starr; C V Fletcher; S A Spector; F H Yong; T Fenton; R C Brundage; D Manion; N Ruiz; M Gersten; M Becker; J McNamara; L M Mofenson; L Purdue; S Siminski; B Graham; D M Kornhauser; W Fiske; C Vincent; H W Lischner; W M Dankner; P M Flynn Journal: N Engl J Med Date: 1999-12-16 Impact factor: 91.245
Authors: Brian Eley; Mary-Ann Davies; Patti Apolles; Carol Cowburn; Heloise Buys; Marco Zampoli; Heather Finlayson; Spasina King; James Nuttall Journal: S Afr Med J Date: 2006-09
Authors: K Henry; A Erice; C Tierney; H H Balfour; M A Fischl; A Kmack; S H Liou; A Kenton; M S Hirsch; J Phair; A Martinez; J O Kahn Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1998-12-01
Authors: Kunjal Patel; Miguel A Hernán; Paige L Williams; John D Seeger; Kenneth McIntosh; Russell B Van Dyke; George R Seage Journal: Clin Infect Dis Date: 2008-06-01 Impact factor: 9.079
Authors: Lydia Feinstein; Andrew Edmonds; Vitus Okitolonda; Stephen R Cole; Annelies Van Rie; Benjamin H Chi; Papy Ndjibu; Jean Lusiama; Jean L Chalachala; Frieda Behets Journal: J Acquir Immune Defic Syndr Date: 2015-07-01 Impact factor: 3.731
Authors: Dwight E Yin; Meredith G Warshaw; William C Miller; Hannah Castro; Susan A Fiscus; Lynda M Harper; Linda J Harrison; Nigel J Klein; Joanna Lewis; Ann J Melvin; Gareth Tudor-Williams; Ross E McKinney Journal: Pediatrics Date: 2014-10 Impact factor: 7.124
Authors: Michael Schomaker; Matthias Egger; James Ndirangu; Sam Phiri; Harry Moultrie; Karl Technau; Vivian Cox; Janet Giddy; Cleophas Chimbetete; Robin Wood; Thomas Gsponer; Carolyn Bolton Moore; Helena Rabie; Brian Eley; Lulu Muhe; Martina Penazzato; Shaffiq Essajee; Olivia Keiser; Mary-Ann Davies Journal: PLoS Med Date: 2013-11-19 Impact factor: 11.069